IRONWOOD PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $897.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $453.00K, a 8.37% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $444.00K, a 8.56% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $435.00K, a 8.21% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $426.00K, a 8.40% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.69M, a 8.34% increase from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.56M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $897.00K 10-Q · filed 2026-08-06 | $1.33M derived: sum of 3 quarters · filed 2026-08-06 | $1.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $444.00K 10-Q · filed 2026-05-07 | $879.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.30M derived: sum of 3 quarters · filed 2026-05-07 | $1.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $861.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $1.69M 10-K · filed 2026-02-26 |
| 2025-09-30 | $426.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $844.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.25M 10-Q · filed 2025-11-10 | $1.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $827.00K 10-Q · filed 2026-08-06 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $1.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $409.00K 10-Q · filed 2026-05-07 | $811.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.20M derived: sum of 3 quarters · filed 2026-05-07 | $1.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $795.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.18M derived: sum of 3 quarters · filed 2026-02-26 | $1.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $778.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.16M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $385.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $763.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $378.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |